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A B S T R A C T
Objective: To determine the cost-effectiveness (as measured as cost per life-year saved) of
white blood cell growth factor or colony-stimulating factor (CSF) use among a large cohort of
elderly non-Hodgkin’s lymphoma (NHL) patients in a real-world setting.
Methods: We identified 13,203 NHL patients from the Surveillance, Epidemiology, and End
Results (SEER)-Medicare database who received the diagnosis from 1992 to 2002 and who re-
ceived chemotherapy within 12 months of diagnosis. Benefit (effectiveness) of CSF use (primary
and secondary prophylaxis) was measured as observed improvement in overall survival. Costs
for each patient were calculated by adding the cumulative reimbursement amounts from Medi-
care claims. Cost-effectiveness was estimated by modeling the joint influence of CSF use on
both costs and effectiveness using a propensity-score net monetary benefit approach.
Results: Primary prophylactic CSF use was cost-effective at lower willingness-to-pay
thresholds, whereas at higher thresholds, not providing prophylactic CSF became the cost-
effective strategy. For secondary prophylactic CSF use among patients experiencing neu-
tropenia, fever, and/or infection, the opposite trend was observed. For low willingness-to-
pay thresholds ($20,000 per life-year gained), not administering CSF was the cost-effective
strategy, whereas CSF use became cost-effective as willingness to pay increased (from
$100,000 per life-year gained).
Conclusion: To our knowledge, this is the first large population-based study to empirically
measure the cost-effectiveness of CSF among NHL patients treated with chemotherapy. CSF
use as primary or secondary prophylaxis may be a cost-effective strategy depending on
society’s (or payers’) willingness to pay for improvements in outcomes.
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Non-Hodgkin’s lymphoma (NHL) is the fifth most common
noncutaneous cancer in the United States in both men and
women, with an estimated 66,120 people diagnosed in 2008
[1]. Furthermore, NHL is the second fastest increasing cancer
in terms of incidence and mortality. Since the 1970s, the inci-
dence of NHL has nearly doubled [2]. Although intensive che-
motherapy can be highly effective in the treatment of NHL, it
has been well-documented that the myelosuppressive effect
of chemotherapy leads to increases in febrile neutropenia, in-
fections, and hospitalizations, which add significant burden to
the patients in terms of health, quality of life, and economic
burden [3,4]. Granulocyte-colony stimulating factors (G-CSFs)
and granulocyte-macrophage colony-stimulating stimulating
factors (GM-CSFs) are supportive care agents intended to de-
crease the myelosuppressive effects of chemotherapy by
stimulating the bone marrow to produce granulocytes and
stem cells and also by enhancing the survival of existing neu-
trophils. There is strong clinical evidence that G-CSF and GM-
CSF (collectively referred to as colony-stimulating factors
[CSFs]) used during the initial cycles of chemotherapy leads to
a reduction of febrile neutropenia events and subsequent in-
fection [5,6]. To date, however, there is little evidence that
hese improvements in intermediate outcomes lead to im-
rovements in longer term outcomes such as progression-free
urvival [7–9] or overall survival [7,10].
The well-established link between CSF use and improve-
ents in intermediate outcomes such as reduced incidence of
ebrile neutropenia and infections have prompted many pro-
essional organizations to recommend the prophylactic use of
SF in patients treated with chemotherapy, especially among
he elderly. For example, recently updated American Society
f Clinical Oncology (ASCO) recommendations consider age as
one of the conditions for which prophylactic use of growth
actors may be indicated irrespective of the threshold risk of
eutropenia” [11]. Although the evidence of improvements in
ntermediate outcomes is strong, with growing constraints on
ealth-care dollars, in conjunction with an aging population,
t is likely that consideration of long-term outcomes and over-
ll cost-effectiveness will also be considered in determining
he overall value of CSF use in the future.
Several studies have evaluated the costs and cost-effec-
iveness of CSF use [12–15]. Initial cost studies were conducted
rom a cost-minimization perspective and found that CSF use
esulted in decreased overall costs among subsets of patients
ho had a high risk of febrile neutropenia [12,13]. Few eco-
omic evaluations have been conducted within the setting of
HL. A study of only 23 patients [14] measuring CSF use
mong older patients with NHL receiving chemotherapy
ound overall treatment costs to be lower among patients who
eceived G-CSF. In another NHL-specific cost-benefit evalua-
ion [15], it was found that among NHL patients receiving a
ommon chemotherapy regimen, CSF use at the recom-
ended dose resulted in overall cost neutrality. Some cost
avings, however, were observed at lower doses. Doorduijn
t al. [7] found that adding G-CSF in elderly patients with NHL
as not cost-effective. The purpose of this current study waso use data on a large nationwide and population-based co-
ort of elderly NHL patients treated with chemotherapy to
irectly measure the cost-effectiveness (measured as cost per
ife-year saved) of CSF use in a real-world setting.
Patients and methods
Data source
This study used data from the merged Surveillance, Epidemi-
ology, and End Results (SEER)–Medicare database. The SEER
database program is a population-based registry sponsored by
the National Cancer Institute that contains information on all
newly diagnosed cancer cases that occur in 12 SEER partici-
pating areas, including the metropolitan areas of San Francis-
co/Oakland, Detroit, Atlanta, rural Georgia, Seattle, Los Ange-
les County, the San Jose-Monterrey area, and the states of
Connecticut, Iowa, New Mexico, Utah, and Hawaii. SEER data
are highly valid and the completeness of case ascertainment
is 98%.
The SEER registry collects information on patient demo-
graphics, tumor characteristics, stage at diagnosis, treatment
within 4 months of diagnosis, and date and cause of death.
The registry data are linked to claims data from Medicare,
which is the primary insurer for 97% of the US population 65
years and older. All Medicare beneficiaries receive part A cov-
erage, which covers inpatient care, skilled nursing, home
health, and hospice care. Ninety-five percent of beneficiaries
also subscribe to part B of Medicare to obtain benefits that
cover physician services and outpatient care [16]. The Com-
mittee for the Protection of Human Subjects at the University
of Texas Health Science Center at Houston approved this
study.
Study population and patient characterization
The retrospective cohort study included incident NHL pa-
tients who received a diagnosis during the period January 1,
1992, to December 13, 2002, who received chemotherapy
within 12 months of diagnosis. Patients enrolled in an HMO
during any period of the study period were excluded because
data were unavailable for these periods. Patients who did not
participate in both Medicare parts A and B during any month
were also excluded.
Patients were characterized with respect to clinical and de-
mographic variables available in the SEER-Medicare data.
Chemotherapy and radiation therapy were characterized and
quantified using International Classification of Diseases (ICD)
diagnosis codes, ICD Procedural codes, Current Procedural
Terminology (CPT) codes, Healthcare Common Procedural
Coding System (HCPCS) codes, and revenue center codes [16].
The following codes were used for defining chemotherapy:
ICD-9 CM procedure code 9925 for chemotherapy infusion/
injection; CPT codes 96400–96549, J9000–J9999 codes, and
Q0083–Q0085; revenue center codes 0331, 0332, and 0335; and
ICD-9 V codes V58.1, V66.2, and V67.2. Chemotherapy use was
stratified by type (e.g., alkylating agent, topoisomerase II in-
hibitors, anthracyclines, and antimetabolites) using HCPCS
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255V A L U E I N H E A L T H 1 4 ( 2 0 1 1 ) 2 5 3 – 2 6 2codes. The use of CSF was identified by the CPT codes J1440
and J1441 (for G-CSF) and J2820 (for GM-CSF). Primary prophy-
laxis was identified as CSF administered concurrently with
chemotherapy before the incidence of neutropenia, fever,
and/or infection. Secondary prophylactic CSF use was de-
fined as CSF administered after the occurrence of neutrope-
nia, fever, and/or infection. Neutropenia was defined by the
following ICD codes: neutropenia hospitalization (288.0),
neutropenia (288.0) with or without fever (780.6). Infection
was defined by the ICD-codes 001.0 –139.8. Comorbidities
were aggregated to formulate the National Cancer Institute
comorbidity index, a revised version of the Charlson Co-
morbidity Index [17].
Data analysis and cost calculation
Patients were described with respect to demographic and
clinical characteristics overall and stratified by CSF status
(primary prophylaxis, yes vs. no; secondary prophylaxis,
yes vs. no). Chi-square tests (for categorical variables) and t
tests (for continuous variables) were used to identify statis-
tically significant differences in patient characteristics by
CSF status.
To adjust for difference in comparison groups by CSF (yes
or no) in the evaluation of costs, effectiveness, and cost-effec-
tiveness, a propensity score was used. A propensity score is a
measure of the likelihood of a subject being assigned to a par-
ticular treatment group. Adjustment using a propensity score
was reported to remove the bias of the background covariates
substantially [18,19] and may also control for biases intro-
duced by certain unknown or unmeasured covariates that are
associated with measured factors [20]. Briefly, the propensity
score was calculated by conducting a logistic regression anal-
ysis in which the dependent variable was CSF status and in-
dependent variables included all demographic, clinical, and
treatment characteristics that were predictive of CSF status.
Because we evaluated the cost-effectiveness of primary and
secondary CSF use, we calculated separate propensity scores:
one based on the likelihood of having received primary pro-
phylactic CSF and one based on the likelihood of receiving
secondary prophylactic CSF.
Benefit (effectiveness) of CSF use was measured as ob-
served improvement in overall survival. For the evaluation of
the effectiveness of primary prophylactic CSF use, all patients
were followed-up with from the initiation of chemotherapy
through death or end of the study period (October 31, 2006)
and compared overall survival among patients who received
primary prophylactic CSF with those who did not. For the eval-
uation of the effectiveness of secondary prophylactic CSF use,
we included only patients who experienced neutropenia, fe-
ver, and/or infection and compared overall survival in pa-
tients who received secondary prophylactic CSF with those
who did not. Comparisons of survival by CSF status were made
using Cox proportional hazards regression analysis adjusting
for propensity score.
The cost analysis was conducted from a payer’s perspec-
tive. As such, we measured only direct costs as captured in
Medicare claims data. Costs for each patient were calculated
by adding the cumulative reimbursement amounts derived ffrom claims in the Medicare inpatient, outpatient, physician,
and the hospice/home health files beginning from the date of
first chemotherapy administration (for evaluation of overall
CSF use and primary prophylactic CSF use) or from the date of
initial neutropenia/fever/infection event (for evaluation of
secondary CSF use). These starting dates were selected to cap-
ture the time period in which CSF use would potentially affect
cost and outcomes. Costs were captured until the date of
death or date of last follow-up (October 31, 2006). Costs were
calculated overall and by major cost categories for the pur-
poses of identifying underlying cost drivers behind observed
differences in treatment cohorts. Cost categories were created
based on diagnosis and procedure codes. Differences in cost
by CSF status were compared using linear regression analysis
adjusting for propensity score. A 3% annual discount rate was
applied to measures of cost and effectiveness.
We used a propensity score–adjusted net monetary benefit
approach to estimate cost-effectiveness. The net monetary
benefit approach for estimating cost-effectiveness is highly
amenable to observational data insomuch as it allows for the
modeling of the joint density of costs and effectiveness using
standard regression techniques and leads to a less biased es-
timate of cost-effectiveness in the presence of significant dif-
ferences in baseline measures between treatment groups in
observational studies [21,22]. The net monetary benefit ap-
proach also overcomes the statistical limitations inherent to
the traditional cost-effectiveness ratio (i.e., discontinuity of
incremental cost-effectiveness ratio as the difference in effec-
tiveness approaches zero) [23,24].
Uncertainty of the net monetary benefit was illustrated
via cost-effectiveness acceptability curves [25–28]. These
curves were created by plotting the probability that CSF was
cost-effective across a range of plausible willingness–to-pay
thresholds. This probability was calculated based on P val-
ues from the net monetary benefit linear regression analy-
ses across the range of ceiling thresholds. This method of
presenting the cost-effectiveness under conditions of un-
certainty is useful in that one can easily determine the point
above which statistical significance is reached [23]. An
added advantage is that one can also impute the relative
influence of cost versus effectiveness in the net monetary
benefit estimates [26].
Results
We identified 13,203 NHL patients who received chemother-
apy within 12 months of diagnosis and met the eligibility cri-
teria for this study. The median age at diagnosis was 74 years
(range, 65–102). Fifty-three percent (n 7051) of patients were
emale, and a large majority (n  11,776; 90%) were non-His-
anic white and lived in an urban setting (n  11,877; 90%).
orty-four percent (n  5861) of patients had a diagnosis of
iffuse large B-cell lymphoma, 18% (n  2428) had follicular
ymphoma, 28% (n  3665) had other histologies, and 9% (n 
249) had an unknown histology. Because of the reported re-
iability for differentiating certain subtypes in the SEER data
29], we specifically identified diffuse large B-cell lymphoma and
ollicular lymphoma while grouping the remaining histologic
256 V A L U E I N H E A L T H 1 4 ( 2 0 1 1 ) 2 5 3 – 2 6 2Table 1 – Patient demographic and clinical characteristics by CSF use.
Variable Primary prophylaxis Secondary prophylaxis*
No
(n  11,864)
Yes
(n  1339)
P No
(n  4020)
Yes
(n  4526)
P
Year of diagnosis
1992–1993† 1726 (14.5) 33 (2.5) 795 (19.8) 280 (6.2)
1994–1995 1654 (13.9) 183 (13.7) 538 (13.4) 578 (12.8)
1996–1997 1698 (14.3) 214 (16.0) 542 (13.5) 698 (15.4)
1998–1999 1649 (13.9) 203 (15.2) 510 (12.7) 678 (15.0)
2000–2001 3296 (27.8) 482 (36.0) 905 (22.5) 1608 (35.5)
2002 1841 (15.5) 224 (16.7) 0.001 730 (18.2) 684 (15.1) 0.001
Age at diagnosis, y
Mean (SD) 75.0 (6.4) 74.8 (6.0) 0.26 75.2 (6.4) 74.3 (5.9) 0.001
Median (range) 74 (65–102) 74 (65–97) 75 (65–102) 74 (65–98)
65–69† 2799 (23.6) 291 (21.7) 877 (21.8) 1105 (24.4)
70–74 3200 (27.0) 398 (29.7) 1082 (26.9) 1351 (29.8)
75–79 2959 (24.9) 365 (27.3) 1044 (26.0) 1179 (26.0)
80–84 1910 (16.1) 197 (14.7) 680 (16.9) 637 (14.1)
85 996 (8.4) 88 (6.6) 0.007 337 (8.4) 254 (5.6) 0.001
Sex†
Male 5508 (46.4) 644 (48.1) 1867 (46.4) 2117 (46.8)
Female 6356 (53.6) 695 (51.9) 0.25 2153 (53.6) 2409 (53.2) 0.76
Race/ethnicity
White 10,588 (89.2) 1188 (88.7) 3587 (89.2) 4075 (90.0)
Hispanic 215 (1.8) 21 (1.6) 145 (3.6) 131 (2.9)
Black 400 (3.4) 41 (3.1) 111 (2.8) 131 (2.9)
Asian 350 (3.0) 54 (4.0) 54 (1.3) 88 (1.9)
Other/unknown 311 (2.6) 35 (2.6) 0.35 123 (3.1) 101 (2.3) 0.01
Urban residence
No 1198 (10.1) 128 (9.6) 441 (11.0) 332 (7.3)
Yes 10,666 (89.9) 1211 (90.4) 0.43 3579 (89.0) 4194 (92.7) 0.001
Marital status
Yes 6985 (58.9) 812 (60.6) 2311 (57.5) 2833 (62.6)
No 4358 (36.7) 480 (35.8) 1558 (38.8) 1518 (33.5)
Unknown 521 (4.4) 47 (3.5) 0.22 151 (3.8) 175 (3.9) 0.001
SES quartiles
1 (high) 3078 (25.9) 298 (22.3) 1029 (25.6) 1245 (27.5)
2 2929 (24.7) 322 (24.0) 957 (23.8) 1159 (25.6)
3 2952 (24.9) 353 (26.4) 1043 (25.9) 1050 (23.2)
4 (low) 2725 (23.0) 340 (25.4) 925 (23.0) 1008 (22.3)
Missing 180 (1.5) 26 (1.9) 0.02 66 (1.6) 64 (1.4) 0.009
Stage
I 3246 (27.4) 318 (23.7) 1040 (25.9) 1136 (25.1)
II 1992 (16.8) 222 (16.6) 642 (16.0) 755 (16.7)
III 1726 (14.5) 245 (18.3) 573 (14.3) 774 (17.1)
IV 4033 (34.0) 486 (36.3) 1475 (36.7) 1579 (34.9)
Unknown 867 (7.3) 68 (5.1) 0.001 290 (7.2) 282 (6.2) 0.002
Histology
Diffuse large B-cell 5175 (43.6) 686 (51.2) 1763 (43.9) 2177 (48.1)
Follicular 2223 (18.7) 205 (15.3) 698 (17.4) 801 (17.7)
Other 3329 (28.1) 336 (25.1) 1137 (28.3) 1190 (26.3)
Unknown 1137 (9.6) 112 (8.4) 0.001 422 (10.5) 358 (7.9) 0.001
Comorbidity score
0 7401 (62.4) 815 (60.9) 2401 (59.7) 2851 (63.0)
1 2817 (23.7) 331 (24.7) 980 (24.4) 1068 (23.6)
2 1646 (13.9) 193 (14.4) 0.56 639 (15.9) 607 (13.4) 0.001
(continued on next page)
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257V A L U E I N H E A L T H 1 4 ( 2 0 1 1 ) 2 5 3 – 2 6 2subtypes as other. Patient distribution by stage at diagnosis was
27% (n3564) stage I, 17% (n2214) stage II, 15% (n1971) stage
II, and 34% (n 4519) stage IV. More than 60% of patients receiv-
ng CSF had a comorbidty score of 0 or 1.
Table 1 shows patient demographic, clinical, and treat-
ent characteristics overall and by CSF use. Among all pa-
ients (N  13,203), 10% (n  1339) received primary prophy-
actic CSF. The most notable clinical/demographic differences
etween these patients and those who did not receive primary
rophylactic CSF were that patients receiving primary pro-
hylactic CSF were diagnosed more recently and had more
atients with diffuse large B-cell lymphoma. With regard to
reatment, patients receiving primary prophylactic CSF were
ore likely to receive chemotherapy agents associated with a
igh risk of myelosuppression, have a greater number of che-
otherapy claims, and undergo radiation therapy.
Overall, 8546 patients (64%) experienced neutropenia, fe-
er, and/or infection during or after chemotherapy. Of these,
526 patients (53%) received secondary prophylactic CSF after
hese events. These patients differed significantly from pa-
ients who did not receive secondary prophylactic CSF with
espect to date of diagnosis (more recent), histology (more
ikely to have diffuse large B-cell lymphoma), comorbidity sta-
us (lower comorbidity index), chemotherapy agent and dura-
ion, and radiation therapy status. There were other signifi-
ant differences in terms of age at diagnosis, race/ethnicity,
nd marital status between these groups.
Propensity score–adjusted overall survival estimates by
SF are presented in Figure 1. Among all patients, there was
ittle observed difference in overall survival (hazard ratio [HR]
.05; 95% confidence interval [CI] 0.96–1.16; P  0.35) between
atients receiving primary prophylactic CSF (median overall
urvival [OS] 3.6 years; 95% CI 2.8–4.3) compared with those
ho did not (median OS 3.8 years; 95% CI 3.7–4.0). In patients
Table 1 (continued)
Variable Primary proph
No
(n  11,864)
Yes
(n  13
Chemotherapy agent
Alkylating 9736 (82.1) 1215 (90
Topoisomerase II inhibitors 2931 (24.7) 397 (29
Anthracyclines 6140 (51.8) 928 (69
Antimetabolites 2813 (23.7) 335 (25
Platinums 441 (3.7) 79 (5.9
Taxanes 112 (0.9) 20 (1.5
Vinca alkaloids 9522 (80.3) 1196 (89
Nonanthracycline antibiotics 639 (5.4) 72 (5.4
Targeted (biologics) 6191 (52.2) 746 (55
Other 1750 (14.8) 191 (14
No. of chemotherapy claims
Mean (SD) 18.4 (22.6) 23.4 (26
Median (range) 11 (1–393) 14 (1–
Radiation therapy
No 7405 (62.4) 789 (58
Yes 4459 (37.6) 550 (41
* Among patients who experienced neutropenia, fever, and/or infect
† Values shown are number (%) unless otherwise indicated.ho experienced neutropenia, fever, and/or infection, the use jf secondary prophylactic CSF was associated with signifi-
antly greater overall survival (HR 0.87; 95% CI 0.82–0.92; P 
.001). After neutropenia, fever, and/or infection, the median
S for patients receiving secondary prophylactic CSF was 3.1
ears (95% CI 2.8–3.3) compared with 2.3 years (95% CI 2.2–2.5)
or patients who did not.
Table 2 shows average total costs for patients by CSF status
verall and by category and also presents propensity score–
djusted cost differences by CSF status. Overall, patients re-
eiving primary prophylactic CSF had a higher average total
ost of care ($163,048) compared with patients who did not
eceive primary prophylactic CSF ($150,674). This difference
ersisted across cost category; patients who received primary
rophylactic CSF had higher hospitalization costs (including
ebrile neutropenia–related and infection-related hospitaliza-
ions) and also had higher nonhospital febrile neutropenia–
elated and infection-related costs. Given that there were sig-
ificant differences in potential confounding factors by CSF
tatus, we calculated a propensity score–adjusted cost differ-
nce and found that total costs, after controlling for propen-
ity of receiving primary prophylactic CSF, were significantly
ower for patients receiving primary prophylactic CSF com-
ared with those not receiving primary prophylactic CSF (ad-
usted mean cost difference$28,228; P 0.001). The propen-
ity score for primary prophylactic CSF use incorporated year
f diagnosis, sex, marital status, radiation therapy, stage at
iagnosis, urban residence, age at diagnosis, histology, num-
er of chemotherapy claims, and chemotherapy agent. Simi-
ar to observed differences by primary prophylaxis, we found
hat among patients who experienced neutropenia, fever,
nd/or infection, those who received secondary prophylactic
SF had a higher mean total cost of care ($187,826) compared
ith those who did not (mean total cost $107,524). After ad-
usting for propensity, this difference persisted, with the ad-
s Secondary prophylaxis*
P No
(n  4020)
Yes
(n  4526)
P
0.001 3396 (84.5) 4209 (93.0) 0.001
0.001 995 (24.8) 1547 (34.2) 0.001
0.001 2110 (52.5) 3051 (67.4) 0.001
0.287 945 (23.5) 1385 (30.6) 0.001
0.001 110 (2.7) 337 (7.4) 0.001
0.06 26 (0.6) 77 (1.7) 0.001
0.001 3301 (82.1) 4123 (91.1) 0.001
0.99 273 (6.8) 259 (5.7) 0.04
0.01 2127 (52.9) 2605 (57.6) 0.001
0.63 677 (16.8) 680 (15.0) 0.02
0.001 15.9 (17.5) 29.4 (30.7) 0.001
10 (1–170) 19 (1–394)
2578 (64.1) 2706 (59.8)
0.01 1442 (35.9) 1820 (40.2) 0.001ylaxi
39)
.7)
.6)
.3)
.0)
)
)
.3)
)
.7)
.3)
.3)
273)
.9)
.1)
ion.usted cost difference being $21,901 higher for patients receiv-
258 V A L U E I N H E A L T H 1 4 ( 2 0 1 1 ) 2 5 3 – 2 6 2ing secondary prophylactic CSF (P  0.001). The propensity
score for secondary prophylactic CSF use incorporated diag-
nosis year, histology, age at diagnosis, urban status, number
of chemotherapy claims, and chemotherapy agent. Another
Adjusted* overall survival – primary CSF (p=0.35) 
   Adjusted HR* 
(95% CI)  Median  OS 
(95% CI) 
CSF no 3.8 years (3.7 – 
4.0)  
 1.00 
CSF
yes
3.6 years (2.8 – 
4.3)
 1.05 (0.96 – 
1.16)
CSF yes 
CSF no 
Fig. 1 – Overall survival by CSF use. *Adjusted for propensity
survival.
Table 2 – Comparison of costs by CSF use.
Cost category Crude mean total cost* by CS
Primary prophylactic CSF use
among all patients
S
No
(n  11,864)
Yes
(n  1339)
Total $150,674 (139,256) $163,048 (133,094) $
All hospitalizations $25,432 (29,983) $27,070 (32,216)
Febrile neutropenia-related
hospitalizations
$2061 (0) $2,255 (0)
Infection-related
hospitalizations
$2,514 (0) $2,783 (0)
Other febrile neutropenia-
related
$10,230 ($5779) $12,831 ($6756)
Other infection-related 82 (0) $120 (0)
CSF $1593 (797) $4236 (5,600)
* 3% per year discount rate applied.
† Cost period starts at initial febrile neutropenia/infection date after initiaobservation worth noting is that patients who did not receive
primary prophylactic CSF often received secondary prophy-
lactic CSF after neutropenia, fever, and/or infection, hence the
observed mean CSF cost of $1593 among these patients.
Adjusted* overall survival – secondary CSF 
(p<0.001) 
   Adjusted HR* 
(95% CI)  Median OS 
(95% CI) 
CSF no 2.3 years (2.2 – 
2.5)
 1.00 
CSF
yes
3.1 years (2.8 – 
3.3)
 0.87 (0.82 – 
0.92)
CSF yes 
CSF no 
re. CI, confidence interval; HR, hazard ratio; OS, overall
(interquartile range) Propensity-score adjusted cost
difference (CSF yes/no)
(P value)
dary prophylactic CSF use
ng patients experiencing
rile neutropenia event†
Primary, yes
vs. no
Secondary,
yes vs. no
No
 4020)
Yes
(n  4526)
24 (102,505) $187,826 (161,153) $28,228 (0.001) $21,901 (0.001)
42 (26,950) $29,457 (32,989) $234 (0.80) $3,380 (0.001)
17 (5,237) $3,355 (5,190) 157 (0.38) $23.51 (0.89)
23 (5,863) $3,729 (4,054) $10.52 (0.97) $565 (0.04)
94 ($2108) $26,584 ($24,467) $3147 (0.002) $10,596 (0.001)
71 (248) $649 (179) $39.91 (0.34) $116 (0.20)
— $5064 (5,922) $1599 (0.001) —scoF use
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259V A L U E I N H E A L T H 1 4 ( 2 0 1 1 ) 2 5 3 – 2 6 2Finally, we estimated the cost-effectiveness of primary and
secondary prophylactic CSF use by modeling the net monetary
benefit of these strategies. Crude and propensity score–adjusted
net monetary benefit and corresponding 95% CI across a range of
willingness-to-pay thresholds are presented in Table 3, with cor-
responding cost-effectiveness acceptability curves presented in
Figure 2. For primary prophylactic CSF use, we found that this
strategy was cost-effective at lower willingness-to-pay thresh-
olds, whereas at higher thresholds, not providing prophylactic
CSF became the cost-effective strategy. In this situation, there is
a slightly negative survival effect. This loss in benefit, however, is
offset by the cost savings associated with CSF when the willing-
ness to pay is relatively low, such that net monetary benefit is
positive. With higher levels of willingness to pay, the cost of
reduced survival is not offset by the cost savings, resulting in a
negative net monetary benefit. For example, given that a payer is
willing to pay only $10,000 per life-year gained, then administer-
ing primary prophylactic CSF yields a net monetary benefit of
$24,385 (95% CI $16,116–$32,655) after adjusting for propensity
score. On the opposite end of the spectrum, if a payer is willing to
spend as much as $1,000,000 per life-year gained, then the ob-
Table 3 – Net monetary benefit analysis on CSF as primary
Ceiling ratio
($/life-year
saved)
Crude net monetary benefit (95% CI)
Primary prophylaxis Secondary prophyl
$10,000 $15,845 ($25,171 to $6519) $75,777 ($82,552 to 
$20,000 $19,300 ($28,822 to $9,778) $69,669 ($76,506 to 
$50,000 $29,664 ($41,673 to $17,655) $51,347 ($59,667 to 
$100,000 $46,938 ($66,304 to $57,572) $20,810 ($33,977 to 
$250,000 $98.759 ($144,907 to $52,612) $70,802 ($39,401–$102
$500,000 $185,128 ($277,831 to $92,426) $223,489 ($160,183–$28
$1,000,000 $357,867 ($544,407 to $171,326) $528,860 ($401,179–$65
CI, confidence interval.
* Included only patients who experienced neutropenia, fever, and/orFig. 2 – Cost-effectiveness accserved cost savings of primary prophylactic CSF use becomes
overwhelmed by a very high willingness to pay. In this case, not
administering primary prophylactic CSF use yields a net mone-
tary benefit of $356,038 (95% CI $544,752–$167,323). At the typical
norm for willingness to pay of $100,000 per life-year gained, pri-
mary prophylactic CSF has a negative net monetary benefit of
$10,199. There is, however, considerable uncertainty around
this estimate, with a 95% CI of$29,346 to $8949.
For secondary prophylactic CSF use among patients expe-
iencing neutropenia, fever, and/or infection, the opposite
rend was observed. For low willingness-to-pay thresholds
$20,000 per life-year gained), not administering CSF was the
ost-effective strategy, whereas CSF use became cost-effec-
ive as willingness to pay increased (from $100,000 per life-
ear gained).
Discussion
Cancer care cost is escalating at a rate of 15% per year, nearly
threefold the increase in overall health-care spending [30]. As
hylaxis or secondary prophylaxis.
Propensity-score adjusted monetary benefit (95% CI)
Primary prophylaxis Secondary prophylaxis*
01) $24,385 ($16,116–$32,655) $17,899 ($24,600 to $11,199)
33) $20,542 ($12,025–$29,060) $13,886 ($20,709 to $7062)
27) $9014 ($2322 to $20,351) $1846 ($10,514 to $6822)
) $10,199 ($29,346 to $8949) $18,220 ($4028–$32,412)
$67,839 ($114,393 to $21,284) $78,419 ($44,214–$112,625)
$163,905 ($257,658 to $70,152) $178,751 ($109,828–$247,673)
$356,038 ($544,752 to $167,323) $379,414 ($240,550–$518,278)
tion.prop
axis*
$69,0
$62,8
$42,0
$7642
,203)
6,793)
6,541)eptability curves by CSF.
260 V A L U E I N H E A L T H 1 4 ( 2 0 1 1 ) 2 5 3 – 2 6 2the increases in cost continue to outpace the expansion of
available resources, it will become increasingly important to
conduct sound economic evaluations to identify the most ef-
fective, efficient, and equitable means of allocating health-
care resources. To the best of our knowledge, this is the first
study to empirically measure the cost-effectiveness of CSF
among a large cohort of NHL patients treated with chemother-
apy. Our results suggest that as willingness to pay increases,
primary prophylactic CSF use becomes less favorable,
whereas secondary prophylactic CSF becomes more favor-
able. This conclusion is based on the observation that primary
prophylactic CSF was less costly but did not translate to in-
creased effectiveness, whereas secondary prophylactic CSF
was more costly and was associated with greater effective-
ness. For primary prophylaxis, we found that administering
CSF was cost-effective at lower willingness-to-pay thresholds,
which was in agreement with general patterns of cost-effec-
tiveness acceptability curves (CEACs) of interventions that
have point estimates showing slightly lower effectiveness (in
this case, not statistically significant) and significantly lower
associated costs. This is a perverse outcome from a clinical
perspective because costs are saved at the expense of lower
life expectancy. On the other hand, secondary prophylactic
CSF became cost-effective as willingness to pay increased.
Again, the observed CEAC was typical for interventions that
are more costly and more effective than the alternative strat-
egy. Uncertainty surrounding our cost-effectiveness esti-
mates was evaluated by calculating the CIs of the calculated
net monetary benefit across a range of willingness-to-pay
thresholds. The use of multivariable regression techniques al-
lowed us to model the net monetary benefit while adjusting
for propensity score. This strategy has been demonstrated to
be an effective method for addressing uncertainty and poten-
tial confounding factors when estimating cost-effectiveness
using observational data [21,22].
The majority of studies to date that have addressed the
economics of CSF have been conducted from a cost-minimi-
zation perspective. The initial cost study of CSF use came in
1993 [12] in the form of a cost-minimization study nested
within a randomized, controlled trial. This study found that
CSF use reduced overall costs in patients who had a risk of
febrile neutropenia exceeding a threshold of 40%. An updated
analysis of the same data with a more comprehensive inclu-
sion of costs found that the threshold febrile neutropenia risk
level for cost savings was 10% to 25% [13]. The 40% risk thresh-
old for cost savings has persisted in the literature as the stan-
dard [31]. Various cost-effectiveness analyses have suggested
that CSF use is associated with cost-effectiveness ratios well
below the standard threshold of $50,000 per life-year gained
[32–35]. Many of these studies rely on the assumed improve-
ment of long-term outcomes based on observed benefits of
intermediate outcomes such as sustained full-dose leading to
prevention of infection-related mortality or disease recur-
rence. Results of the current study found that secondary pro-
phylactic CSF, although not cost-effective at the $50,000 per
life-year-gained threshold, did become cost-effective at the
$100,000 per life-year gained threshold. Economic evaluations
conducted in the setting of NHL [7,15,36] have yielded conflict-
ing results. These studies, unlike the current study, did notconsider total costs of care but rather included only costs that
were directly attributed to CSFs. An advantage of considering
total costs of care is that it includes related costs that may not
be identified as such.
This study had its limitations. Although generalizable to
the elderly Medicare population, results may have limited ap-
plication to younger populations and to populations covered
under private managed care. With the aging population of the
United States, however, it will become increasingly important
to focus attention on this demographic cohort. Although we
used propensity-score adjustments to control for underlying
differences between patients receiving CSF and those who did
not, the observational nonrandomized nature of the study
leaves open the possibility of residual confounding. Because
this study was conducted from a payer’s perspective, only di-
rect costs captured in claims data were included. To capture
true total costs, we would also need to consider indirect costs.
Because we did not include indirect costs such as travel costs
and costs for missing work or loss of leisure time, it is likely
that our cost estimates underestimated the true total costs
involved. Furthermore, because we relied on claims for esti-
mating direct costs, there is a possibility that costs might have
been underestimated because of missing claims. Perhaps, the
greatest limitation of the study dealt with the lack of adjust-
ment for quality of life. It is possible that CSF use has a sub-
stantial effect on quality of life given the well-established link
between CSF use and decreased incidence of febrile neutrope-
nia, infection, and hospitalizations [37–39]. It is therefore
likely that the incorporation of quality-of-life adjustments
(i.e., use of quality-of-life adjusted life-years) might increase
the estimated effectiveness of CSF use and could plausibly
alter the observed cost-effectiveness of CSF use in a positive
direction. Future studies should focus on the development
and application of methods for incorporating quality of life
based on identified health states through the use of claims
data.
The strength of this study lies in the fact that the cost-
effectiveness of CSF use was measured directly using data
from a cohort of geographically dispersed population-based
elderly NHL patients treated with chemotherapy. Although
this is the first study to attempt to estimate the real-world
cost-effectiveness of CSF use in this population, similar vali-
dated methods for estimating cost of care using SEER-Medi-
care data have been used in several studies in the past
[21,22,40,41]. The significance of this study from a policy per-
spective stems from the fact that NHL is a rapidly growing
cancer in terms of incidence and prevalence, and therefore it
will be increasingly important to identify the most cost-effec-
tive means by which to manage it. Although the observational
nature of the study was vulnerable to a significant likelihood
of confounding, we attempted to account for this by applying
propensity-score approaches to control for baseline differ-
ences in comparison groups. Finally, although previous stud-
ies dealing with costs have often reverted to a cost-minimiza-
tion strategy, we chose to conduct an economic evaluation by
modeling the joint density of costs and effects through a net
monetary benefit analysis approach. The rationale for con-
ducting cost-minimization analyses has historically revolved
around the notion that it is appropriate to base policy/
a
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261V A L U E I N H E A L T H 1 4 ( 2 0 1 1 ) 2 5 3 – 2 6 2treatment decisions solely on cost when all things appear
equal from a clinical outcomes standpoint. This perspec-
tive, however, has been debunked by economists [42] who
rgue that it is not appropriate to assume that, if there is no
tatistically significant difference in outcomes, the out-
omes are the same [43].
Conclusion
In conclusion, CSF use, whether used as primary or secondary
prophylaxis, may be cost-effective depending on a payer’s (or
society’s) willingness to pay. Future studies should attempt to
evaluate the generalizability of these results by evaluating
cost-effectiveness of CSF use in different patient populations.
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